Atorvastatin dose and PCI timing predict hypoperfusion in STEMI patients

Photo by Aakash Dhage / Unsplash

Frontiers in Medicine Published April 21, 2026 Medically reviewed April 25, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Note that atorvastatin dose and PCI timing are associated with hypoperfusion in this STEMI cohort.

This cohort study included 434 patients with acute ST-segment elevation myocardial infarction (STEMI) who underwent primary PCI at a hospital. The primary outcome was myocardial hypoperfusion, assessed against a comparator of normal perfusion. The study phase and publication type were not reported.

Analysis identified independent predictors of myocardial hypoperfusion. These predictors included time from onset to primary PCI, atorvastatin dose before PCI, balloon deflation method during PCI, red cell distribution width (RDW), and monoamine oxidase (MAO) levels. All findings had P < 0.05. Absolute numbers and specific effect sizes were not reported.

Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported. The study did not report limitations, funding sources, or conflicts of interest. Follow-up duration was not reported.

Given the observational design, the findings describe associations rather than establishing causality. Clinicians should interpret these results with caution regarding the role of atorvastatin dose and other factors in predicting myocardial hypoperfusion during primary PCI.

Study Details

Study typeCohort

EvidenceLevel 3

PublishedApr 2026

View Original Abstract ↓

ObjectiveTo analyze the determinants of myocardial hypoperfusion following primary percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) and to develop a risk prediction model.MethodsClinical data from 434 patients with STEMI who underwent primary PCI at our hospital between January 2023 and June 2025 were retrospectively collected. Patients were randomly assigned to a training cohort (n = 304) and a validation cohort (n = 130) at a 7:3 ratio. Based on postprocedural myocardial perfusion, the training cohort was further divided into a hypoperfusion group (n = 103) and a normal perfusion group (n = 201). Candidate variables were screened using Boruta and least absolute shrinkage and selection operator (LASSO) regression, followed by multivariable logistic regression to identify independent predictors. A risk prediction model was constructed using R software and visualized as a nomogram. Model performance and clinical utility were evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).ResultsMultivariable logistic regression identified time from onset to primary PCI, atorvastatin dose before PCI, balloon deflation method during PCI, red cell distribution width (RDW), and monoamine oxidase (MAO) levels as independent predictors of myocardial hypoperfusion (all P